Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 4/20 | 0.69 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.69 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.69 |
| ▸ | PDE2A | O00408 | 3/20 | 0.69 |
| ▸ | PDE5A | O76074 | 13/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.54 |
| ▸ | CFTR | P13569 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.54 |
| ▸ | PDE6C | P51160 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL897036 | 0.82 | PDE1A (1.00) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL6869474 | 0.81 | PDE1A (0.72) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL2917588 | 0.80 | PDE5A (0.74) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL516338 | 0.79 | GAA (0.62) | CYP3A4MEN1KMT2AGAAMAPT | |
| SCHEMBL10960174 | 0.78 | PDE1A (0.69) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL9121409 | 0.78 | PDE1A (1.00) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL14889319 | 0.78 | PDE5A (1.00) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL4622439 | 0.78 | PDE5A (0.73) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL782824 | 0.76 | PDE5A (1.00) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL10960178 | 0.76 | PDE5A (0.70) | PDE1APDE1BPDE1CPDE2APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050163759-A1 | Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of type I and/or type II phosphodiesterases | ST. CAMILLUS MEDICAL, INC. | 2005-07-28 | — | — | US | claimed |
| WO-2005054437-A2 | COMPOSITIONS AND METHODS FOR EX VIVO PRESERVATION OF BLOOD VESSELS FOR VASCULAR GRAFTS USING INHIBITOR OF TYPE I AND/OR TYPE II PHOSPHODIESTERASES | ST. CAMILLUS MEDICAL, INC. (US) | 2005-06-16 | — | — | WO | claimed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | claimed |
| US-20180291374-A1 | INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-11 | — | — | US | disclosed |
| US-20170226507-A1 | COORDINATE CONTROL OF PATHOGENIC SIGNALING BY THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION AND FIBROPROLIFERATIVE DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9388412-B2 | Inhibitors of microRNAs that regulate production of atrial natriuretic peptide (ANP) as therapeutics and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| WO-2016077574-A1 | INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2015171641-A1 | COORDINATE CONTROL OF PATHOGENIC SIGNALING BY THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION AND FIBROPROLIFERATIVE DISEASES | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-5968911-A | ADMINISTERING NITRIC OXIDE PRECURSORS OR DERIVATIVES, PHOSPHODIESTERASE INHIBITORS OR CYCLIC NUCLEOTIDES INTO TRACHEA OR BRONCHI IN AEROSOL FORM | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-10-19 | — | — | US | disclosed |
| US-5552267-A | PHOSPHODIESTERASE INHIBITORS, GLUCOSE, MAGNESIUM IONS, BUFFERS, MAGNESIUM IONS AS MACROMOLECULES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1996-09-03 | — | — | US | disclosed |
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | disclosed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | disclosed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | PDE1A 24/4885PDE1B 26/4885PDE1C 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.